Albert Benjamin 4

What Happened

• Albert Benjamin, CEO and director of Health Catalyst (HCAT), was granted 1,124 performance-based restricted stock units (PRSUs) on April 29, 2026. The award is reported at $0.00 per share because it is a contingent PRSU award tied to 2025 performance and board approval.
• On May 1, 2026, 310 shares were disposed of at $1.34 per share (proceeds ≈ $417). This disposal was to satisfy tax withholding obligations in connection with vested restricted stock units and was a mandatory "sell to cover," not a discretionary sale.

Key Details

• Transaction dates and prices: Grant (A) on 2026-04-29 — 1,124 PRSUs @ $0.00; Tax-withholding sale (F) on 2026-05-01 — 310 shares @ $1.34 (≈ $417).
• Shares owned after transaction: Not specified in the excerpt of the filing provided.
• Footnotes: F1 — PRSUs are contingent rights to one share each based on 2025 performance (board approved 4/29/2026). F2 — The 310-share sale was a mandatory sell-to-cover for tax withholding under the issuer’s equity plans and not a discretionary trade.
• Filing timeliness: Form 4 was filed 2026-05-01 reporting a 2026-04-29 grant and a 2026-05-01 tax-withholding sale; the filing appears timely based on the transaction dates.

Context

• PRSUs are performance-contingent awards that convert to shares only if specified performance goals are met; they are not an immediate cash purchase. The small sale was routine tax withholding, which is common and generally not interpreted as an expression of market sentiment by the insider.